Lonza Capsules and Health Ingredients | Contract Pharma

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lonza Capsules and Health Ingredients | Contract Pharma

Search by

Lonza Capsules and Health Ingredients

Company Headquarters

412 Mt. Kemble Ave. , Morristown, NJ, 07960, US

Driving Directions Phone: View Phone Fax: View Fax

View website

Request more information from Lonza Capsules and Health Ingredients

Request more information from Lonza Capsules and Health Ingredients

Yes, Please subscribe me to your weekly eNewsletters and Alerts

Yes, I wish to receive special promotions and offers from your affiliates.

Yes, I would like to learn more about Lonza Capsules and Health Ingredients. Please contact me by Phone or Email

By completing this form, you are accepting our Terms of Use and Privacy Policy.

Categories from Lonza Capsules and Health Ingredients

505(b)(2)

Analytical Laboratory Services

Animal Health

Anti-Counterfeiting Technology

Bioavailability Studies

Coating & Lamination

Distribution, Clinical Trials

Dosage Form Development

Drug Delivery Systems

Drug Design

Drug Development Services

Encapsulation

Excipients

Filling, Capsule

Formulation Development

Formulation Services

Formulation, Controlled Release

Hot Melt Extrusion

Manufacturing Equipment and Supplies

Manufacturing, API

Manufacturing, Bioequivalence

Manufacturing, Capsules

Manufacturing, Clinical Trials Supply

Manufacturing, Generics

Manufacturing, Inhalables

Manufacturing, Liquids

Manufacturing, Oral Drug Delivery

Manufacturing, OTC

Manufacturing, Soft Gels

Manufacturing, Solid Dosage

Microdosing

Micronization

Packaging, Anti-Counterfeiting

Packaging, Capsules

Packaging, Clinical Trial Materials

Packaging, Clinical Trials

Particle Characterization

Particle Size Analysis

Preformulation

Supplier, Excipients

Library

Lonza Continues to Lead the Market with Innovative Hard Empty Capsules

Sponsored Content

Lonza Continues to Lead the Market with Innovative Hard Empty Capsules

Lonza’s Capsugel® capsules provide High-quality products and support services to enable your drug delivery and development.

Released By Lonza Capsules and Health Ingredients

Double-blinding and removing bias with over-encapsulation

White Papers / Tech Papers

Double-blinding and removing bias with over-encapsulation

While there are many blinding options available, over-encapsulation remains the most popular method adopted by sponsors to meet regulatory demands.

Released By Lonza Capsules and Health Ingredients

Capsule Delivery Solutions from Lonza Pharma & Biotech

Sponsored Content

Capsule Delivery Solutions from Lonza Pharma & Biotech

Capsule Delivery Solutions, part of Lonza Pharma & Biotech, is the leader in capsule-based solutions and services, proudly offering Capsugel® products.

Released By Lonza Capsules and Health Ingredients

Related Content

Lonza Bend Facility

Breaking News

Lonza to Add Commercial Spray-Drying Facility in Oregon

The facility is expected to be completed in 2029, and will add 80 new jobs.

By: Patrick Lavery

lonza samanta cco

Promotions & Moves

Lonza Names Samanta Cimitan Chief Commercial Officer

Cimitan will lead strategic accounts, global marketing and commercial excellence.

By: Charlie Sternberg

Breaking News

Lonza Launches Rapid Media Prototyping Service

New RaMP service provides custom liquid and powder media batches within 10 working days.

By: Charlie Sternberg

Biologics_MC1_Visp_034_840x454

White Papers / Tech Papers

Navigating the BLA Pathway: A Guide to Analytical Characterization of Complex Molecular Formats

Lonza's new white paper shows how modern analytics — from MAM to automated glycan analysis — turn complex biologics characterization into a competitive advantage.

Released By Lonza

lonza engitix

Collaborations & Alliances

Lonza, Engitix Ink ADC Licensing Deal

Engitix will use Lonza’s ADC platform to advance precision therapeutics for patients with chronic diseases.

By: Charlie Sternberg

Breaking News

Lonza Acquires Rights to Nona Biosciences’ TfR1 Blood-Brain Barrier Tech

Nona’s BBB technology, combined with Lonza’s biologics and bioconjugation capabilities, aims to enable development for central nervous system therapies.

By: Kristin Brooks

Breaking News

Lonza Expands HPAPI Capacity in Visp

Will establish new commercial-scale capabilities for the manufacture of complex and highly potent active pharmaceutical ingredients and ADC payload-linkers.

By: Kristin Brooks

Lonza booth at BIO 2026

Online Exclusives

AI in Biologics CDMO Workflows: A BIO Conversation with Lonza

There is still trial and error, but AI is now demonstrably impacting CDMOs across the entire value chain.

By: Patrick Lavery

Collaborations & Alliances

Lonza, InduPro Enter Licensing Agreement for Next-Gen ADCs

InduPro to license Lonza’s linker payload technologies and bioconjugation platforms to help advance its ADC therapeutics.

By: Kristin Brooks

lonza ammax

Collaborations & Alliances

AmMax Bio, Lonza Enter Non-Exclusive Licensing Agreement for AMB-104

AMB-104 provides a unique solution to address venetoclax/azacitidine resistance in acute myeloid leukemia (AML).

By: Charlie Sternberg

Promotions & Moves

Lonza Appoints Hans Trees as Global Head of Communications

Hans is a seasoned communications executive with broad experience across communications, strategy and business leadership in global organizations.

By: Kristin Brooks

lonza atipple

Collaborations & Alliances

Lonza, Stipple Bio Sign ADC Licensing Deal

Agreement supports development of next-generation precision oncology therapies, including STP-100.

By: Charlie Sternberg

Breaking News

Lonza Enhances Biologics Preclinical Development Offering

DNA‑to‑IND offering leveraging GS Ori‑Go designed to deliver tox material in approximately two months, and IND readiness in as little as six months.

By: Kristin Brooks

Collaborations & Alliances

Oxford Nanopore and Lonza Launch mRNA QC Solution for GMP Testing

Combines direct RNA sequencing, machine learning, and automated analysis to simplify GMP.

By: Charlie Sternberg

Breaking News

Lonza Launches Xcite AAV Producer Cell Line Platform

Addresses manufacturing challenges related to scalability, cost of goods and process consistency as gene therapy programs move toward commercialization.

By: Charlie Sternberg